Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Please check the URL.

We're sorry, but the page you are looking for cannot be accessed. It may have been removed, had its name changed, may be temporarily unavailable, or the URL address may have been entered incorrectly.

Please click here to continue.